Table 2

Relationship between PSA at diagnosis and features related to tumor significance in biopsy specimens (placebo group only)

PSA (ng/mL)
0-1.01.1-2.52.6-4.04.1-10.0>10
No. subjects16135219223812
Gleason score5.98 (0.54)6.08 (0.61)6.43 (0.95)6.55 (0.94)6.92 (1.16)
66667
No. cores positive 1.32 (0.63)1.61 (0.90)2.02 (1.44)2.17 (1.56)2.00 (1.13)
11222
Percent cores positive20.0 (10.0)25.7 (14.7)31.2 (19.2)32.1 (20.0)32.5 (19.0)
16.716.725.027.326.7
Greatest linear extent (mm)1.63 (1.48)2.24 (2.04)3.09 (2.64)3.55 (3.23)3.91 (3.32)
1.101.602.252.603.70
Aggregate linear extent (mm)2.06 (2.39)3.29 (3.97)5.37 (7.39)6.54 (8.71)6.25 (7.32)
1.151.803.003.405.05
Bilateral (%)8.715.621.526.033.3
Perineural invasion (%)1.28.313.412.50.0
Median prostate volume (cm3)27.231.936.140.031.9
Median PSA density (ng/mL/g)0.030.050.090.120.48
Insignificant cancer (%; criteria 1)*51.733.717.811.70.0
Insignificant cancer (%; criteria 2)55.438.817.213.50.0

NOTE: Numbers represent mean, (SD), and median from top to bottom unless otherwise noted.

  • * Stage T1c + PSA density <0.15 ng/mL/g + Gleason score ≤6 (no pattern 4 or 5) + tumor limited to <3 cores + no core with >50% involvement.

  • Stage T1c + PSA density <0.15 ng/mL/g + Gleason score ≤6 (no pattern 4 or 5) + tumor limited to <3 mm on 1 core.